Additionally, bortezomib attenuates the secretion of IL-6 and VEGF by endothelial cells [204] and decreases vessel density in xenografts of squamous cell carcinoma [205], suggesting that bortezomib may target tumor-associated angiogenesis. This evidence concerns the gene IL6 and neoplasm.